Biosimilar uptake still limited in the U.S.

The European Medicines Agency approved the first biosimilar in Europe in 2006. It was almost 10 years before the United States followed. Despite potential savings for payers and patients, biosimilar uptake in the U.S. remains limited.In a virtual presentation for the Interdisciplinary Autoimmune Summit, Jonathan Kay, MD, from UMass Memorial Medical Center, said the potential risk of an individual switching to a lower-cost biosimilar should be outweighed by the potential benefit of expanded access.“The availability of biosimilars should decrease the cost of treating patients,” heRead More

Share on facebook
Share on twitter
Share on linkedin